Smoking habits and erlotinib response in non-small-cell lung cancer (NSCLC) treatment Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Chemotherapy improves low performance status lung cancer patients Source: Eur Respir J 2007; 30: 1186-1192 Year: 2007
Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006
Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
Influence of dose of radiotherapy on quality of life in patients with non-small cell lung cancer treated by radiotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 495s Year: 2005
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018
Management of patients with non-small-cell lung cancer Source: ERS Live 2007 Year: 2007
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002
The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004